Abstract
Metabolic response monitoring early during chemotherapy may have a major impact on clinical management of patients with malignant lymphoma. In two patients with non-Hodgkin's lymphoma fluorine-18 fluorodeoxyglucose (IgFDG) single-photon emission tomography (SPET) studies were performed during the first two chemotherapeutic cycles. Persisting uptake predicted treatment failure whereas a sharp reduction of 18FDG uptake was demonstrated in the case of a responsive tumour. Qualitative analysis of conventional 18FDG imaging may thus serve to identify patients with a non-responding tumour. The potential of this technique in the determination of the initial response remains to be established. Imaging with 18FDG and SPET appears promising as a more easily available methodology than 18FDG positron emission tomography.
Original language | English |
---|---|
Pages (from-to) | 1214-1217 |
Number of pages | 4 |
Journal | European journal of nuclear medicine |
Volume | 20 |
Issue number | 12 |
DOIs | |
Publication status | Published - Dec 1993 |
Keywords
- Chemotherapy
- Fluorine-18 fluorodeoxyglucose
- Malignant lymphoma
- Response monitoring
- Single-photon emission tomography